Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errorsiTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Large-scale genetic testing can read many DNA variants at once, but the number of variants measured does not tell you how useful the result is. For common diseases, a polygenic risk score (PRS) combines information from many variants to estimate risk; it is a statistical prediction, not a diagnosis. Its value depends on the score’s evidence, how well it applies to the person tested, and whether the result can guide effective care.
What does large-scale gene scanning mean?
It is a broad label for methods that measure many genetic variants in one test, then interpret some of those findings in relation to health. The measurement technology and the interpretation method are separate things: sequencing may produce genetic data, while a PRS or another analysis uses selected data to estimate a particular kind of risk.
The U.S. Food and Drug Administration describes next-generation sequencing (NGS) as technology capable of rapidly sequencing large sections of a person’s genome. That technical capability does not, by itself, show that a particular disease-risk estimate is accurate or useful for care. FDA, “Precision Medicine”
Different methods answer different questions
| Approach | What it does | What it does not establish by itself |
|---|---|---|
| Next-generation sequencing (NGS) | A technology for sequencing many DNA regions or variants at once. | That every variant relevant to a disease was detected, interpreted, or shown to change health outcomes. |
| Whole-exome sequencing (WES) | Sequences the exome, the genome’s protein-coding regions, for analysis. | A complete view of all genetic variation or a validated common-disease risk estimate. |
| Whole-genome sequencing (WGS) | Sequences a much broader portion of the genome for analysis. | That a broader sequence automatically gives a more clinically useful answer. |
| Polygenic risk score (PRS) | Combines the effects of many selected variants into a statistical estimate for a particular outcome. | A diagnosis, a guarantee that disease will or will not occur, or proof that using the score improves health. |
WES and WGS are sequencing approaches; a PRS is an interpretation method. A score may use genetic data from a sequencing test or another genotyping method. “More genes” or “more variants” is not a sound way to rank tests without considering the specific disease question and evidence behind the result.
#1 Best Overall
- TOP-SELLING CONSUMER DNA TEST: From your origins in over 3,600 places around the world to the most connections to living relatives, no other DNA test kit delivers an experience as unique and interactive as AncestryDNA.
- YOUR DATA, YOUR CONTROL: We give you full control over your genetic information. You decide what to share, and with whom.
- A FEW SIMPLE STEPS: Simply activate your DNA kit online and return your saliva sample in the prepaid package to our state-of-the-art lab. Your results will be available online in roughly six weeks.
- ORIGINS AND INHERITANCE: AncestryDNA provides more precise ancestral origins with greater geographic detail. Our innovative SideView technology takes your results even further by showing your origins and matches by parental side. *Some DNA features require an Ancestry subscription.
- BUILD YOUR FAMILY TREE: Combine what you learn from your DNA results with an Ancestry subscription and gain access to millions of family trees and the world's largest collection of online family history records. *Access to record collections varies depending on subscription level.
How can a genetic test estimate risk for a common disease?
Many common diseases are multifactorial: risk reflects many genetic contributions along with non-genetic influences. A PRS weights and combines selected variants based on statistical associations with a disease or outcome. The resulting estimate is probabilistic. It may indicate that someone’s risk is relatively higher or lower within a defined comparison, but it cannot determine whether that person will develop the disease.
A low PRS does not rule out meaningful risk. Family history, age, clinical history, and other relevant factors remain important. The American College of Medical Genetics and Genomics (ACMG) says PRS results are statistical predictions of increased clinical risk, not diagnoses, and warns that a low score does not exclude significant risk. ACMG, “The clinical application of polygenic risk scores: A points to consider statement” (2023)
Rank #2
- REVIEW IMPORTANT TEST INFO: There is a lot to consider with genetic testing. Before purchasing, review important information about Genetic Health Risk* and Carrier Status* reports at 23andme. org/test-info. A portion of your purchase may be eligible for FSA/HSA reimbursement***.
- UNDERSTAND YOUR GENETIC HEALTH: Get 10+ Condition reports* that show whether you have genetic variants associated with a higher risk of certain conditions. Includes FDA-authorized reports, and you choose whether to view certain reports.
- PLAN AHEAD WITH 45+ CARRIER STATUS REPORTS*: Discover if you carry a genetic variant for inherited conditions across categories like blood, lung, and hearing health, information you can bring to family planning conversations with your healthcare provider.
- OPTIMIZE YOUR DAILY WELLNESS: See how your genes may influence lifestyle factors like deep sleep, lactose intolerance, genetic weight, and muscle composition.
- MAP YOUR ORIGINS ACROSS 5,000+ REGIONS: Explore your Ancestry Composition, trace maternal and paternal haplogroups (paternal requires a Y chromosome), and dig into your Neanderthal Ancestry. Opt in to find up to 1,500 DNA Relatives, and your Family Tree builds itself automatically.
Population fit affects what a score means
A score’s predictive value can be poor when the population in which it was developed differs from the person receiving it. Performance should not be assumed to be equal across ancestry groups—or across all people who share a broad ancestry label. Ask whether the specific score has been evaluated in a population and use case relevant to you. ACMG highlights population differences as a limitation in applying PRS. ACMG’s 2023 points-to-consider statement
Recommended Free Tools
How should a large-scale test be evaluated?
Four questions help separate a technically sound test from one that can support a health decision. They concern the test’s ability to measure variants, the evidence connecting those variants to an outcome, whether acting on the result helps, and the safeguards around offering testing.
Rank #3
- REVIEW IMPORTANT TEST INFO: There is a lot to consider with genetic testing. Before purchasing, review important information about Genetic Health Risk*, Carrier Status*, and Pharmacogenetics** reports at 23andme. org/test-info and 23andme. org/test-info/pharmacogenetics. A portion of your purchase may be eligible for FSA/HSA reimbursement***.
- UNDERSTAND YOUR GENETIC HEALTH: Receive 160+ personalized genetic reports, including 50+ Conditions* and wellness reports. Get insights into heart health, metabolic health, mental health, and more. You choose whether to view certain reports.
- TRACK HEALTH GOALS: Health Tracks(SM) show how everyday choices may shape your health over time. Opt in to the Family Health History Tree to input and track information to share with your healthcare provider.
- PLAN AHEAD WITH 45+ CARRIER STATUS REPORTS*: Find out whether you carry a genetic variant for inherited conditions across categories like blood, lung, and hearing health, information you can bring to family planning conversations with your healthcare provider.
- LEARN HOW YOUR BODY MAY RESPOND: FDA-authorized pharmacogenetics reports show how your DNA may impact the way your body processes certain medications**, including some used in heart health and mental health care. Talk to your healthcare provider before making any medication changes.
1. Analytical validity: Did the lab measure the variants reliably?
Analytical validity concerns whether a laboratory accurately and reliably detects the variants it claims to measure. NGS-based tests require validation appropriate to their design and intended use. FDA guidance addresses analytical validation for NGS-based in-vitro diagnostics intended to aid diagnosis of suspected germline diseases; it should not be read as validation of every common-disease score or screening product. FDA, “Considerations for Design, Development, and Analytical Validation of NGS-Based IVDs Intended to Aid in the Diagnosis of Suspected Germline Diseases” (April 2018)
2. Clinical validity: Does the result predict the stated outcome?
Clinical validity asks whether a detected variant or score predicts or detects the specific disease or outcome claimed, for the intended population and use. Association is not the same as causation: a common variant may be statistically associated with increased risk without being either necessary or sufficient for disease. Evidence should include appropriate replication and testing in a representative population. NHGRI, “Promoting Safe and Effective Genetic Testing in the United States — Chapter 2”
Rank #4
- ABOUT THE TEST: The Genetrace DNA Paternity Test helps families conclusively determine if a man is the true father of a child.
- NO HIDDEN FEES: Kit includes all lab fees and sample return costs to test one (1) child and one (1) potential father.
- FAST RESULTS: Get secure, confidential results within 1-2 business days after testing begins. We'll keep you updated every step of the way.
- EASY SAMPLE COLLECTION: No needles, no blood, no doctors. Collect your samples with our easy-to-use mouth swabs, then return them to the lab with the provided prepaid return envelope. It's quick, easy & painless.
- ACCURATE & RELIABLE: Up to 27 genetic markers analyzed for over 99.999% accuracy. All tests performed TWICE in our AABB, ISO 17025 & CLIA accredited laboratory.
3. Clinical utility: Does using the result improve a decision or outcome?
Clinical utility asks whether acting on a result helps with diagnosis, treatment, management, or prevention. A valid risk estimate is not automatically useful: its value depends on whether it changes a decision in a beneficial way and whether an evidence-based response is available. Technical scale and statistical significance do not answer that question. The ACMG population-screening guidance emphasizes that potential benefits depend on linking risk identification to evidence-based risk-reducing care. ACMG, “DNA-based screening and population health: Points to consider for programs and sponsoring organizations” (2021)
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →4. Ethical, legal, and social implications: Are the safeguards appropriate?
Testing programs also need to consider informed consent, privacy, effects on family members, equitable access, and how results will be explained and followed up. The USPSTF’s technical brief describes the ACCE framework, which includes these ethical, legal, and social implications alongside analytic validity, clinical validity, and clinical utility. USPSTF, “Genomic Testing for Screening or Disease Risk Prediction” (2021)
Best Value
- The Most Accurate Breed Detection: Screen for 430+ breeds— to get a breed report down to 1%. Because knowing every detail helps you understand how to care for them
- Unlock 30 Essential Health Insights: Screen for genetic health tests (including MDR1 and IVDD) to get ahead of health risks and create a personalized care plan with your vet
- Meet Their Relatives: 99.9% of dogs tested have a relative match through Wisdom Panel. With the world’s largest breed database and 5 million dogs tested, you can see photos, compare DNA results, and send messages
- Learn About Their Traits and Behaviors: Know them better inside and out. Wisdom Panel screens for 51 traits so you can learn how their one of a kind appearance came to be. Plus, understand their individual quirks with insights into 3 unique behavioral tendencies
- 5m+ Pets Tested In 60+ Countries: Wisdom Panel is the world’s leading dog DNA service thanks to its quick, painless swabbing process, fast and accurate results, and reliable insights you can use for years to come
How is screening different from diagnostic testing?
Screening is generally offered to people without a prior indication of disease, to identify possible risk or need for follow-up. Diagnostic testing is usually prompted by symptoms, family history, or other evidence that raises the likelihood of a specific condition. The same genetic technology may be used in different contexts, but evidence for one use does not automatically establish suitability for the other. ACMG discusses personal health and population screening separately, including the importance of care pathways after a screening result. ACMG, “DNA-based screening and personal health: Points to consider for individuals and health-care providers” (2021)
What else might a broad scan reveal?
Although this article focuses on common, multifactorial disease, clinical exome or genome screening may also identify findings in other categories, including monogenic disease risks, carrier status, and pharmacogenomic information. These findings are not interchangeable with a PRS: they involve different evidence, meanings, and follow-up pathways. ACMG’s 2021 statement on elective exome and genome testing identifies these as possible categories of findings. NHGRI, “Promoting Safe and Effective Genetic Testing in the United States — Chapter 2”
A result outside the original common-disease question may have implications for the tested person or relatives. Before testing, ask what categories of findings the laboratory will report, whether you can choose what to receive, and who will explain results that need clinical follow-up.
What should you ask before relying on a risk result?
- What exactly is being measured? Identify the sequencing or genotyping method, the variants assessed, and the disease or outcome the result addresses.
- What evidence supports this specific result? Ask whether clinical validity has been demonstrated for the intended use and for a population relevant to you.
- How will the result affect care? Find out whether an established screening, prevention, or treatment decision changes based on the result.
- How will it be interpreted alongside other information? Discuss family history, age, clinical history, and applicable screening guidance rather than treating a score in isolation.
- What happens after an unexpected finding? Clarify consent choices, privacy practices, follow-up, and whether clinical confirmation or a specialist’s interpretation may be needed.
There is no single general accuracy figure that describes all large-scale genetic scanning for common diseases. Any performance claim needs to identify the particular test or score, disease, target population, and intended use. The evidence and clinical response can differ substantially from one application to another.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
